The dynamic nature of PD‐L1 is further compounded by poor uniformity in PD‐L1 IHC antibodies, variable cut‐offs and tumor/immune cell type levels of expression which corresponds to benefit to therapy.14, 21. Here, CD274 is linked to neoplasm.